FDA Might Allow for Faster Approval of Obesity Drugs (VVUS) (ARNA) (OREX)
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
VIVUS (Nasdaq: VVUS), Arena (Nasdaq: ARNA), and Orexigen (Nasdaq: OREX) are under watch as the FDA is said to be evaluating a process to bring obesity drugs to market faster.
Reports today have FDA Commissioner Margaret Hamburg telling scientific advisers that it is considering allowing for smaller clinical trials on new weight-loss pills, antibiotics, and other drugs deemed to be socially beneficial.
Additionally, Hamburg said that doctors might be able to prescribe the drugs faster to patients in dire need under a "special medical use" label.
VIVUS recently launched its Qsymia pill, while Arena/Esai developed BELVIQ, and Orexigen/Takeda are still conducting trials for Contrave.
Reports today have FDA Commissioner Margaret Hamburg telling scientific advisers that it is considering allowing for smaller clinical trials on new weight-loss pills, antibiotics, and other drugs deemed to be socially beneficial.
Additionally, Hamburg said that doctors might be able to prescribe the drugs faster to patients in dire need under a "special medical use" label.
VIVUS recently launched its Qsymia pill, while Arena/Esai developed BELVIQ, and Orexigen/Takeda are still conducting trials for Contrave.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
- Scorpion Capital says short Twist Biosciences
- Nvidia plans China chip shipments with export-compliant AI processor - The Information
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
